MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
9.02
-0.36
-3.84%
Pre Market: 9.06 +0.04 +0.44% 07:55 04/06 EDT
OPEN
9.31
PREV CLOSE
9.38
HIGH
9.35
LOW
8.92
VOLUME
725
TURNOVER
0
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
2.26B
P/E (TTM)
7.47
1D
5D
1M
3M
1Y
5Y
1D
BioCryst names Sandeep Menon chief research and development officer
Reuters · 59m ago
BIOCRYST APPOINTS SANDEEP M. MENON CHIEF RESEARCH AND DEVELOPMENT OFFICER
Reuters · 1h ago
Press Release: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
Dow Jones · 1h ago
Weekly Report: what happened at BCRX last week (0330-0403)?
Weekly Report · 2h ago
BioCryst grants inducement equity awards to 12 new hires under Nasdaq rule 5635(c)(4)
Reuters · 3d ago
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Weekly Report: what happened at BCRX last week (0323-0327)?
Weekly Report · 03/30 09:52
EOG, GitLab, StoneCo, Cipher, BioCryst Insider Shake-Up
TipRanks · 03/28 13:01
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.